Home>Topics>Stocks>Vertex Pharmaceuticals

Vertex Pharmaceuticals VRTX

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. UPDATE 1-FDA panel votes to expand use of Vertex cystic fibrosis drug

      Headlines

      Tue, 21 Oct 2014

      Oct 21 (Reuters) - A U.S. Food and Drug Administration advisory panel on Tuesday voted 13-2 to recommend expanding approval of Vertex Pharmaceuticals Inc's cystic fibrosis drug Kalydeco to include a...

    2. FDA panel votes to expand use of Vertex cystic fibrosis drug

      Headlines

      Tue, 21 Oct 2014

      Oct 21 (Reuters) - A U.S. Food and Drug Administration advisory panel on Tuesday voted 13-2 to recommend expanding approval of Vertex Pharmaceuticals Inc's cystic fibrosis drug Kalydeco to include a wider range of patients with the rare lung disease, the company said.

    3. Ad Comm vote positive for Kalydeco label expansion

      Headlines

      Tue, 21 Oct 2014

      The Pulmonary-Allergy Drugs Advisory Committee votes 13 - 2 in favor of a label expansion for Vertex Pharmaceuticals ' ( VRTX +3.6% ) cystic fibrosis med Kalydeco (ivacaftor) to include the R117H mutation. This expands the approved CF mutation list to ten. Post your comment!

    4. Vertex Pharma reports on October 28

      Headlines

      Tue, 14 Oct 2014

      Vertex Pharmaceuticals ( VRTX -1.5% ) will report Q3 results on October 28 after the close. The conference call will begin at 5:00 pm ET. Consensus view is a loss of ($0.63) per share on revenues of $147M. Post your comment!

    5. HCV: The 'C' Stands For Cure

      Headlines

      Tue, 7 Oct 2014

      By Matthew Archer : The recent announcement made by Gilead (NASDAQ: GILD ) to allow Egypt and other developing countries to develop a generic analog of its $1,000-a-day treatment for HCV may initially leave investors puzzled. However, once some important facts are revealed about the HCV virus, the

    6. Positive Outlook For ProQR Therapeutics IPO

      Headlines

      Fri, 26 Sep 2014

      considered groundbreaking as compared to existing gene therapy; small molecule treatments - especially those developed by industry rival Vertex Pharmaceuticals . In light of recent success ProQR is considering filing an Complete Story »

    7. A Favorable Prognosis for This Pharma Stock

      Video Reports

      Thu, 18 Sep 2014

      Stefan Quenneville: We think [TICKER: VRTX ] Vertex Pharmaceuticals ( VRTX ) has a positive moat trend because its recent clinical success in cystic fibrosis positions it as a dominant

      Vertex Pharmaceuticals VRTX found at 0:04

      Stefan Quenneville: We VRTX Vertex Pharmaceuticals ( VRTX ) has a positive moat trend because its recent clinical success in cystic fibrosis positions it as a dominant player in this very
    8. Uncertainty Prevails For Vertex

      Headlines

      Thu, 11 Sep 2014

      By Balanced Investing : Following the successful approval and launch of Incivek, Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) saw its revenue grow overnight in multiple folds in 2011. In no time, the drug crossed its

    9. Managing Expectations, Part II

      Headlines

      Tue, 19 Aug 2014

      which may face some tough competition if Albuferon receives Food and Drug Administration approval. We still think Vertex's VRTX Phase II telaprevir holds the most promise among hepatitis C drugs in development. Human Genome Sciences and partner Novartis

    10. Reinvent Your Practice: Alternatives to Traditional Succession Planning

      Headlines

      Fri, 25 Apr 2014

      Worldwide UTIW Vertex Pharmaceuticals VRTX Walt Disney DIS ..... UTi Worldwide Vertex Pharmaceuticals Economic Moat ..... thinks Vertex's VRTX expertise in chronic ..... Analyst Report: Vertex Pharmaceuticals Walt Disney

    « Prev12345Next »
    Content Partners